The immune response to breast cancer, and the case for DC immunotherapy

Cytotherapy

Volumn 6, Issue 2, 2004, Pages 154-163

  Allan, C P ^a   Turtle, C J ^a   Mainwaring, P N ^b   Pyke, C ^b   Hart, D N J ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Mater Adults Hospital   (Australia)

Author keywords

Breast cancer; Dendritic cell; Immunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS LIGAND; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; MUCIN 1; PACLITAXEL; PEPTIDE DERIVATIVE; PROTEIN P53; PROTEIN S 100; RNA; SURVIVIN; TAMOXIFEN; TELOMERASE REVERSE TRANSCRIPTASE; TETANUS TOXOID; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR ANTIGEN; UNINDEXED DRUG; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ATTENUATION; BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CELL ACTIVATION; CELL FUSION; CELL LYSATE; CLINICAL STUDY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DATA ANALYSIS; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE EXACERBATION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL DOCUMENTATION; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SENTINEL LYMPH NODE; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; VALIDATION PROCESS;

EID: 2642583371     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410005249     Document Type: Review

References (82)

1. Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res 2001;3:95-8.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Tiwari RK, Borgen PI, Wong GY et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992;12:419-25.
4. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
5. Witters L, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep 2002;9:1163-6.
6. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
7. Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
8. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
10. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
11. zum Buschenfelde CM, Hermann C, Schmidt B et al. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002;62:2244-7.
12. Nagorsen D, Scheibenbogen C, Schaller G et al. Differences in T cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int J Cancer 2003;105:221-5.
13. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339-53.
14. Taylor-Papadimitriou J, Burchell JM, Plunkett T et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
15. Rahn JJ, Dabbagh L, Pasdar M et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-82.
16. Feuerer M, Beckhove P, Bai L et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
17. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
18. McDermott RS, Beuvon F, Pauly M et al. Tumor antigens and antigen-presenting capacity in breast cancer. Pathobiology 2002;70:324-32.
19. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
20. Nasu S, Yagihashi A, Izawa A et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res 2002;22:1839-43.
21. Tanaka K, Iwamoto S, Gon G et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
22. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 2003;10:87-95.
23. Andersen MH, Pedersen LO, Capeller B et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964-8.
24. Kirkpatrick KL, Clark G, Ghilchick M et al. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 2003;29:321-6.
25. Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res 2001;3:146-9.
26. Poremba C, Heine B, Diallo R et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002;198:181-9.
27. Vonderheide RH, June CH. A translational bridge to cancer immunotherapy: exploiting co-stimulation and target antigens for active and passive T cell immunotherapy. Immunol Res 2003;27:341-56.
28. Kontani K, Taguchi O, Narita T et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001;84:1258-64.
29. Hillenbrand EE, Neville AM, Coventry BJ. Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours. Br J Cancer 1999;79:940-4.
30. Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-26.
31. Iwamoto M, Shinohara H, Miyamoto A et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003;104:92-7.
32. Coventry BJ, Lee PL, Gibbs D et al. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 2002;86:546-51.
33. Jakub JW, Pendas S, Reintgen DS. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist 2003;8:59-68.
34. Huang RR, Wen DR, Guo J et al. Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast J 2000;6:225-32.
35. Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future. Ann Surg Oncol 2001;8:22S-8S.
36. Wen DR, Hoon DS, Chang C et al. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 1989;30:277-82.
37. Leong SP, Peng M, Zhou YM et al. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 2002;9:82-7.
38. Pinedo HM, Buter J, Luykx-de Bakker SA et al. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF. effect on tumour-draining lymph node dendritic cells. Eur J Cancer 2003;39:1061-7.
39. Gabrilovich DI, Corak J, Ciernik IF et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-90.
40. Sledge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002;29:104-10.
41. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
42. Linehan DC, Goedegebuure PS, Peoples GE et al. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995;155:4486-91.
43. Baxevanis CN, Dedoussis GV, Papadopoulos NG et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994;74:1275-82.
44. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 2001;11:285-95.
45. Schirrmacher V, Feuerer M, Beckhove P et al. T cell memory, anergy and immunotherapy in breast cancer. J Mammary Gland Biol Neoplasia 2002;7:201-8.
46. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999;91:80-5.
47. Menard S, Tomasic G, Casalini P et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997;3:817-9.
48. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7:3025-30.
49. Camp BJ, Dyhrman ST, Memoli VA et al. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 1996;3:176-84.
50. Venetsanakos E, Beckman I, Bradley J et al. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 1997;75:1826-30.
51. Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997;74:492-501.
52. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
53. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
54. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
55. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
56. Cabrera T, Angustias Fernandez M, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996;50:127-34.
57. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998;58:737-42.
58. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002;12:309-15.
59. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002;12:43-50.
60. Gutierrez LS, Eliza M, Niven-Fairchild T et al. The Fas/Fasligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999;54:245-53.
61. Sheen-Chen SM, Chen HS, Eng HL et al. Circulating soluble Fas in patients with breast cancer. World J Surg 2003;27:10-3.
62. Mor G, Kohen F, Garcia-Velasco J et al. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000;73:185-94.
63. Coveney E, Wheatley GH, 3rd, Lyerly HK. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery 1997;122:228-34.
64. Bai L, Beckhove P, Feuerer M et al. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer 2003;103:73-83.
65. Kobayashi T, Shinohara H, Toyoda M et al. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg Today 2001;31:513-6.
66. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu + tumors. Cancer Res 1998;58:4902-8.
67. Disis ML, Grabstein KH, Sleath PR et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
68. Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther 2002;1:486-9.
69. Disis ML, Rinn K, Knutson KL et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99:2845-50.
70. Morse MA, Clay TM, Colling K et al. HER2 dendritic cell vaccines. Clin Breast Cancer 2003;3(Suppl 4):S164-72.
71. Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
72. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
73. Chen Y, Emtage P, Zhu Q et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 2001;8:316-23.
74. Pecher G, Haring A, Kaiser L et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669-73.
75. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-17.
76. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127-33.
77. Morse MA, Nair SK, Boczkowski D et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 2002;32:1-6.
78. Muller MR, Grunebach F, Nencioni A et al. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 2003;170:5892-6.
79. Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Nat/Acad Sci USA 2000;97:2715-8.
80. Xia J, Tanaka Y, Koido S et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003;170:1980-6.
81. Chen D, Xia J, Tanaka Y et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003;109:300-7.
82. Avigan D. Fusions of breast cancer and dendritic cells as a novel cancer vaccine. Clin Breast Cancer 2003;3(Suppl 4):S158-63.